OptiBiotix Health PLC Planned launch of OptiBiotix products with Boots (2789N)

TIDMOPTI

RNS Number : 2789N

OptiBiotix Health PLC

22 September 2023

Opti B i otix Health plc

( "Opti Bi o t ix" or the "Company")

Planned launch of OptiBiotix products with Boots

OptiBi otix Health p lc (AI M : OPTI), a life sciences busi ness d e vel o ping co m p o u n ds to tack le o besit y, high choleste r ol, diabetes and skincare, announces that it has reached agreement to launch its own brands of SlimBiome(R), GoFigure(R), and Snacksmart(R) products online with Boots in Q1 2024 with a potential store launch in May 2024, subject to Boots instore category rebuild.

Boots is one of the largest retailers in the UK and Ireland with 58,000 employees in 2,200 shops across the United Kingdom and Ireland and reported revenues of GBP6.5bn in 2022. Stores range from local pharmacies to large health and beauty shops are primarily located on the high streets, in airports, and in shopping centres. Boots, developed its multichannel and ecommerce business (Boots.com) during the course of the pandemic with its online store generating sales of GBP576m in 2022. Its online business experienced its biggest Black Friday ever in November 2022, taking three orders every second for 14 consecutive hours Boots' online business helps kick off the year strongly (chargedretail.co.uk) and now accounts for 18% of total retail sales.

S tep hen O'Ha r a, CEO of O pti B i oti x, c o mmented : " We are pleased to report the planned launch of our SlimBiome(R), GoFigure(R), and Snacksmart(R) products online with Boots in Q1 2024. This is a first step in building our brand presence with major retailers to support brand awareness and sales growth. OptiBiotix is now building a multichannel presence with major online (Amazon) and in store retailers both nationally (Holland and Barrett, Boots) and internationally (Apollo Pharmacies: India; Nahdi Pharmacies: Saudi Arabia) which will increase brand credibility and awareness."

This announcement contains information which, prior to its disclosure, was considered inside information for the purposes of the UK Market Abuse Regulation and the Directors of the Company are responsible for the release of this announcement.

For further information, please contact:

 
 OptiBiotix Health plc                                   www.optibiotix.com 
 Neil Davidson, Chairman                         Contact via Walbrook below 
 Stephen O'Hara, Chief Executive 
 
 Cairn Financial Advisers LLP (NOMAD)                    Tel: [phone] 
 Liam Murray / Jo Turner / Ludovico Lazzaretti 
 Peterhouse Capital Limited (Broker)                     Tel: [phone] 
 Duncan Vasey / Lucy Williams 
 
 Walbrook PR Ltd                                         Mob: [phone] 
 Anna Dunphy 
 
 

About OptiBiotix - www.optibiotix.com

OptiBiotix Health plc (AIM: OPTI), which was formed in March 2012, brings science to the development of compounds which modify the human microbiome - the collective genome of the microbes in the body - in order to prevent and manage human disease and promote wellness.

OptiBiotix has an extensive R&D programme working with leading academics in the development of microbial strains, compounds, and formulations which are used as active ingredients and supplements. More than twenty international food and healthcare supplement companies have signed agreements with OptiBiotix to incorporate their human microbiome modulators into a wide range of food products and drinks.

OptiBiotix is also developing its own range of consumer supplements and health products. The Company's current areas of focus include obesity, cardiovascular health, and diabetes.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

MSCQFLFLXKLLBBK

(END) Dow Jones Newswires

September 22, 2023 02:00 ET (06:00 GMT)